Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 70/100

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

Key Takeaway: Co-Diagnostics, Inc. has announced the release date for its first quarter 2025 financial results, set for May 8, 2025, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results with analysts. Key management will participate in the call, ensuring direct communication with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of Q1 2025 earnings release indicates financial transparency.
  • Management will engage with analysts during the conference call.
  • The company showcases its innovative diagnostic technologies.

Full Press Release Details

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) --Co-Diagnostics, Inc.(NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast:ir.codiagnostics.comon theEvents & Webcastspage, or accessible directlyhere
Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

Investor Relations Contact:

Andrew BensonHead of Investor Relations+1 801-438-1036investors@codiagnostics.com

Frequently Asked Questions

When will Co-Diagnostics release its Q1 2025 earnings?

Co-Diagnostics will release its Q1 2025 financial results on May 8, 2025.

What time is the earnings call for Q1 2025?

The earnings call will take place at 4:30 p.m. ET on May 8, 2025.

How can I access the Co-Diagnostics webcast?

The webcast can be accessed via the Co-Diagnostics Events & Webcasts page.

Who will be speaking during the earnings call?

Management including CEO Dwight Egan and CFO Brian Brown will speak.

Last updated: Apr 29, 2025